Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. [electronic resource]
Producer: 20101206Description: 159-66 p. digitalISSN:- 1365-2141
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bleomycin -- administration & dosage
- Cisplatin -- administration & dosage
- Cyclophosphamide -- administration & dosage
- Dacarbazine -- administration & dosage
- Doxorubicin -- administration & dosage
- Etoposide -- administration & dosage
- Female
- Humans
- Ifosfamide -- administration & dosage
- Lymphoma, T-Cell, Peripheral -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Prednisone -- administration & dosage
- Survival Analysis
- Treatment Outcome
- Vinblastine -- administration & dosage
- Vincristine -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.